High-Cost Drug Evaluation: Dutch Institute Redu...

By HEOR Staff Writer

May 4, 2026

In High-Cost Drug Evaluation, the Dutch Healthcare Institute Zorginstituut Nederland, announced that the aver...
Accelerating Biotechnology Patient Access in Europe Through Strategic Policy ...
Insulin Substitution Portugal: Implications of Novo Nordisk’s Discontin...
Dementia Pharmacotherapy Guidelines: Emphasizing Non-Pharmacological Approach...
Enhancing Health Technology Assessment Transparency through Digital Innovation
Advancing Supply Chain Resilience in Europe’s Off-Patent Medicines Sector
Medical Device Innovation South Africa: Breaking Down Systemic Barriers
Expanding Access to Hormonal IUDs in South Africa through Generic Innovation
Europe Pharmaceutical Access at a Critical Crossroads Amid U.S. Pricing Policies
Economic Impact of Fragmented Care: Tackling Obesity, Diabetes, and Cardiovas...
Conditional Reimbursement in Chronic Pain Rehabilitation: Navigating Evidence...
Advancing Psychedelic Therapy Access for Treatment-Resistant Mental Illness
HIV Prevention Partnerships: Expanding Access to Lenacapavir for Global Impact